Search
Kairos Pharma Ltd
KAPAAdd to Watchlist
0.370USD
+0.004+1.06%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
7.92MMarket Cap
LossP/E TTM
More Details of Kairos Pharma Ltd Company
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Kairos Pharma Ltd Info
Ticker SymbolKAPA
Company nameKairos Pharma Ltd
IPO dateSep 16, 2024
CEOYu (John S)
Number of employees1
Security typeOrdinary Share
Fiscal year-endSep 16
Address2355 Westwood Blvd. #139
CityLOS ANGELES
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code90064
Phone18184045541
Websitehttps://kairospharma.com
Ticker SymbolKAPA
IPO dateSep 16, 2024
CEOYu (John S)
Company Executives of Kairos Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.35M
-3.47%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
5.57K
-422.25%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
5.57K
-783.53%
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.35M
-3.47%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
5.57K
-422.25%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
5.57K
-783.53%
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
FAQs
Who are the top five shareholders of Kairos Pharma Ltd?
The top five shareholders of Kairos Pharma Ltd are: Dr. John S. Yu, M.D.
How many institutions hold shares of Kairos Pharma Ltd (KAPA)?
As of 2026Q1, 24 institutions hold shares of Kairos Pharma Ltd, with a combined market value of approximately 1.15M, accounting for 5.38% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1122351.00.